ALTH Allos Therapeutics, Inc. (MM)

Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it will report 2008 first quarter financial results on Wednesday, May 7, 2008, before the U.S. financial markets open. Paul L. Berns, President and Chief Executive Officer, and other members of Allos' senior management will provide a company update and discuss results via webcast and conference call on Wednesday, May 7, 2008 at 8:30 AM ET. The webcast of this call will be available from the homepage and the investors/media section of the Company's website, www.allos.com, and will be archived for 30 days. Alternatively, callers may participate in the conference call by dialing 800-762-8779 (domestic) or 480-248-5081 (international). Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, May 16, 2008. Callers can access the replay by dialing 800-406-7325 (domestic) or 303-590-3030 (international). The passcode is 3865346. About Allos Therapeutics Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing small molecule therapeutics for the treatment of cancer.�The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA, process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate�is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkin�s Lymphoma (NHL). For additional information, please visit the Company�s website at www.allos.com. Safe Harbor Statement The 2008 first quarter results press release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.